Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

22.2%

4 terminated/withdrawn out of 18 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

44%

8 trials in Phase 3/4

Results Transparency

64%

9 of 14 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 3
8(47.1%)
Phase 2
7(41.2%)
Phase 1
2(11.8%)
17Total
Phase 3(8)
Phase 2(7)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT05288855Phase 3Terminated

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

Role: lead

NCT05962788Phase 3Terminated

Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

Role: lead

NCT05337124Completed

A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

Role: lead

NCT04701528Phase 2Completed

Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients

Role: collaborator

NCT03021499Phase 3Completed

Aurinia Renal Response in Active Lupus With Voclosporin

Role: lead

NCT00244842Phase 3Completed

Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis

Role: lead

NCT03597464Phase 3Completed

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

Role: lead

NCT05306379Phase 1Completed

Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin

Role: lead

NCT04147650Phase 2Completed

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

Role: lead

NCT03598036Phase 2Terminated

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

Role: lead

NCT03597139Phase 2Completed

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Role: lead

NCT02141672Phase 2Completed

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

Role: lead

NCT02949973Phase 2Completed

Aurinia Early Urinary Protein Reduction Predicts Response

Role: lead

NCT02949999Phase 1Completed

Voclosporin in Healthy Japanese Volunteers

Role: lead

NCT01586845Phase 3Withdrawn

Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation

Role: lead

NCT00270634Phase 2Completed

Study of ISA247 (Voclosporin) in De Novo Renal Transplantation

Role: lead

NCT00408187Phase 3Completed

Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients

Role: lead

NCT00258713Phase 3Completed

A 36-Week Extension to Protocol ISA04-03

Role: lead

All 18 trials loaded